Search

Research

Evidence-based recommendations exist for early discharge (before 48 h) of young infants with fever without source (FWS) at low risk of serious bacterial infections (SBIs). However, concerns regarding the applicability of international data to local contexts may hinder implementation. We aimed to describe the local epidemiology of FWS and evaluate a newly implemented risk-stratification guideline to support practice change.

Research

A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.

Research

Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.

The Vaccine Trials Group was formed in March 1999 to provide a coordinated approach to the development, delivery, assessment and promotion of vaccines.

We are looking for healthy young adults to take part in a study that will help us learn more about a new pertussis vaccine that we hope will offer greater protection from whooping cough.

This is your chance to play a vital role in shaping Australia's COVID-19 vaccine program

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: rhyme@telethonkids.org.au Background The

Coming up in 2021 Contact us We have a a study to suit every age range in 2021!  From babies at just six weeks for the FluBub Study, through to

ATOMIC Ears Study

Pneumococcal Vaccine Study